Published on 22 Dec 2022 on Benzinga via Yahoo Finance
Phio Pharmaceuticals Outlines New PH-762 Program For Common Skin Cancer In US Patients
Phio Pharmaceuticals Corp (NASDAQ: PHIO) said it expects to file an IND in the U.S. in the first half of 2023 for a Phase 1b clinical trial of its INTASYL compound, PH-762.Phio is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells.PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intratumorally in preclinical models, PH-762 primes an anti-tumor immune response and inhibits tumor growth.Related: Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells.Phio is currently conducting a Phase 1b clinical trial of PH-762 for advanced melanoma.Phio expects to commence a US Phase 1b clinical trial early in the 2nd half of 2023. The initial US trial is expected to focus on cutaneous squamous cell carcinoma and other selected cutaneous malignancies.Price Action: PHIO shares are up 4.08% at $0.39 during the premarket session on the last check Thursday.
See more from Benzinga